India, March 20 -- Syngene International Limited has successfully concluded the acquisition of its first biologics manufacturing site in the USA, previously owned by Emergent BioSolutions Inc.. Announced on March 10, 2025, the acquisition was completed by Syngene USA Inc., a wholly owned subsidiary, at a gross value of $36.5 million.
The state-of-the-art facility, equipped with multiple monoclonal antibody (mAbs) manufacturing lines, expands Syngene's total single-use bioreactor capacity to 50,000L. This addition enhances Syngene's ability to provide comprehensive large molecule discovery, development, and manufacturing services.
With this acquisition, Syngene will offer its global customers seamless supply chain continuity from its four ...